trending Market Intelligence /marketintelligence/en/news-insights/trending/aewaswju1ntpv-dd43ggqa2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

A1M Pharma appoints chief medical officer


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

A1M Pharma appoints chief medical officer

A1M Pharma AB appointed Tobias Larsson Agervald as chief medical officer, effective Dec. 1.

Agervald is a senior medical director in Astellas Pharma Inc.'s Global Clinical Development in the Netherlands. He also co-founded the European Renal Association - European Dialysis and Transplantation Association's endorsed Working Group on Mineral and Bone Disorders.

Sweden-based A1M Pharma is developing ROSgard, based on the protein alpha-1-microglobulin, or A1M, to treat pre-eclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to another organ, most often the liver and kidney, as well as acute kidney injury.